PharmaTher

PharmaTher is a Canadian specialty pharmaceutical company focused on developing, acquiring, and commercializing ketamine-based products and related delivery technologies. Its lead commercial asset is KETARx, an FDA-approved ketamine product for anesthesia and sedation in surgical and diagnostic procedures, and the company is also pursuing additional ketamine indications through the 505(b)(2) pathway, including levodopa-induced dyskinesia in Parkinson's disease. Beyond injectable ketamine, PharmaTher is expanding a microneedle patch platform, PharmaPatch, into ketamine, psychedelics, peptides, and GLP-1 applications. The company also has exposure to reformulated oral cepharanthine through its minority stake in Sairiyo Therapeutics. Overall, PharmaTher is positioning itself as a specialty pharma and drug-delivery company centered on ketamine franchise expansion and platform-enabled lifecycle management.